Yeji
CRLconf 0.99

reproxalap — CRL

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease
Event date
April 3, 2025
429 days ago
Sponsor runway
38 mo
$65.0M liquid

Evidence

“On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter ("2025 Complete Response Letter") from the U.S. Food & Drug Administration ("FDA") regarding the Company's resubmitted New Drug Application ("resubmitted NDA") for reproxalap, an investigational drug candidate, for the treatment of dry eye disease.”
Source: 8-K filed 2025-04-03View on EDGAR ↗0001193125-25-072424

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

10 insiders · 0 buys · 1 sells
Grant
2025-06-10
Miller-Rich Nancy
Director
2,413 @ ——
Grant
2025-06-10
JOYCE MARTIN JOSEPH
Director
62,728 @ ——
Grant
2025-06-10
JOYCE MARTIN JOSEPH
Director
1,689 @ ——
Grant
2025-06-10
JOYCE MARTIN JOSEPH
Director
7,238 @ ——
Grant
2025-06-10
Phillips Gary M.
Director
62,728 @ ——
Grant
2025-06-10
Phillips Gary M.
Director
4,825 @ ——
Grant
2025-06-10
Phillips Gary M.
Director
3,619 @ ——
Grant
2025-06-10
Bronstein Ben
Director
62,728 @ ——
Grant
2025-06-10
Bronstein Ben
Director
3,619 @ ——
Grant
2025-06-10
Walker Neal
Director
62,728 @ ——
Grant
2025-06-10
Walker Neal
Director
2,413 @ ——
Grant
2025-06-10
DOUGLAS RICHARD
Director
62,728 @ ——
Grant
2025-06-10
DOUGLAS RICHARD
Director
14,476 @ ——
Grant
2025-06-10
DOUGLAS RICHARD
Director
1,689 @ ——
Grant
2025-06-10
Miller-Rich Nancy
Director
62,728 @ ——
Grant
2025-04-17
Clark William D
Director
76,760 @ ——
Sell
2025-04-03
PERCEPTIVE ADVISORS LLC
10%+ Owner
3,400,000 @ $1.42$4.83M
Grant
2025-03-04
Machatha Stephen
Chief Development Officer
202,427 @ ——
Grant
2025-03-04
Brady Todd C
President and CEO
809,710 @ ——
← All catalysts for $ALDX